Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9034199 | 0.89 | XDH (0.49) | ARXDH | |
| SCHEMBL21246251 | 0.84 | AR (0.45) | AR | |
| SCHEMBL23927017 | 0.80 | XDH (0.42) | ARXDH | |
| SCHEMBL23927052 | 0.80 | XDH (0.45) | ARXDH | |
| SCHEMBL3770255 | 0.80 | CYP11B1 (0.43) | ARXDH | |
| SCHEMBL3599842 | 0.79 | CYP2D6 (0.53) | ARXDH | |
| SCHEMBL2614475 | 0.79 | AR (0.69) | AR | |
| SCHEMBL4698005 | 0.77 | CYP2D6 (0.41) | ARXDH | |
| SCHEMBL25762021 | 0.77 | CYP2D6 (0.41) | ARXDH | |
| SCHEMBL17354624 | 0.76 | AR (0.49) | ARXDH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0365328-B1 | Pyridine derivatives | ZENECA LTD (GB) | 1996-04-03 | — | — | EP | claimed |
| US-5053415-A | Antiischemic, antiinflammatory, antiarthritic agents, cardiovascular disorders | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1991-10-01 | — | — | US | claimed |
| EP-0365328-A2 | Pyridine derivatives | ZENECA LIMITED (GB) | 1990-04-25 | — | — | EP | claimed |
| EP-3237396-B1 | HETEROCYCLIC DERIVATIVES AS RORGAMMA MODULATORS | GENFIT (FR) | 2019-07-03 | — | — | EP | disclosed |
| US-10233177-B2 | TRPV1 vanilloid receptor antagonists with a bicyclic portion | SERENTRIX, LLC | 2019-03-19 | — | — | US | disclosed |
| EP-2552888-B1 | TRPV1 VANILLOID RECEPTOR ANTAGONISTS WITH A BICYCLIC PORTION | SERENTRIX LLC (US) | 2018-09-26 | — | — | EP | disclosed |
| EP-3237396-A1 | HETEROCYCLIC DERIVATIVES AS RORGAMMA MODULATORS | Genfit (FR) | 2017-11-01 | — | — | EP | disclosed |
| US-20170152252-A1 | TRPV1 Vanilloid Receptor Antagonists With A Bicyclic Portion | SERENTRIX, LLC | 2017-06-01 | — | — | US | disclosed |
| US-20160289199-A1 | TRPV1 Vanilloid Receptor Antagonists With A Bicyclic Portion | SERENTRIX LLC (US) | 2016-10-06 | — | — | US | disclosed |
| WO-2016102633-A1 | HETEROCYCLIC DERIVATIVES AS RORGAMMA MODULATORS | GENFIT (FR) | 2016-06-30 | — | — | WO | disclosed |
| US-9216975-B2 | TRPV1 vanilloid receptor antagonists with a bicyclic portion | Serentrix, LLC. (US) | 2015-12-22 | — | — | US | disclosed |
| CN-102858742-B | Trpv1 vanilloid receptor antagonists with a bicyclic portion | PHARMESTE SRL | 2015-05-27 | — | — | CN | disclosed |
| US-20130079339-A1 | TRPV1 VANILLOID RECEPTOR ANTAGONISTS WITH A BICYCLIC PORTION | PHARMESTE S.R.L. (IT) | 2013-03-28 | — | — | US | disclosed |
| EP-2552888-A1 | \"TRPV1 VANILLOID RECEPTOR ANTAGONISTS WITH A BICYCLIC PORTION\ | Pharmeste S.r.l. (IT) | 2013-02-06 | — | — | EP | disclosed |
| CN-102858742-A | Trpv1 vanilloid receptor antagonists with a bicyclic portion | PHARMESTE SRL | 2013-01-02 | — | — | CN | disclosed |
| WO-2011120604-A1 | \"TRPV1 VANILLOID RECEPTOR ANTAGONISTS WITH A BICYCLIC PORTION\ | PHARMESTE S.R.L. (IT) | 2011-10-06 | — | — | WO | disclosed |
| EP-0365328-B1 | Pyridine derivatives | ZENECA LTD (GB) | 1996-04-03 | — | — | EP | disclosed |
| US-5053415-A | Antiischemic, antiinflammatory, antiarthritic agents, cardiovascular disorders | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1991-10-01 | — | — | US | disclosed |
| EP-0365328-A2 | Pyridine derivatives | ZENECA LIMITED (GB) | 1990-04-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170152252-A1 | TRPV1 Vanilloid Receptor Antagonists With A Bicyclic Portion | TRPV1, TRPV5, TRPV3 | AR 1188/4885XDH 1624/4885 |
| US-10233177-B2 | TRPV1 vanilloid receptor antagonists with a bicyclic portion | TRPV1, TRPV5, TRPV3 | AR 1188/4885XDH 1624/4885 |
| US-20160289199-A1 | TRPV1 Vanilloid Receptor Antagonists With A Bicyclic Portion | TRPV1, TRPV5, TRPV3 | AR 1188/4885XDH 1624/4885 |
| US-20130079339-A1 | TRPV1 VANILLOID RECEPTOR ANTAGONISTS WITH A BICYCLIC PORTION | TRPV1, TRPV5, TRPV3 | AR 1188/4885XDH 1624/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.